Prognostic Value of Blood-Based P-Tau217 Levels for Progression to Cognitive Impairment

Rachel F Buckley, Diana L Townsend, Colin J Birkenbihl, Madison Cuppels, Gillian T Coughlan, Mabel T Seto, Jane A Brown, Michael J Properzi, Merle C Hönig, Annie Li, Aaron P Schultz, Jasmeer Chhatwal, Hyun-Sik Yang, Steven Arnold, Pia Kivisäkk, Bryan D James, Sid O'Bryant, Robert A Rissman, Melissa Petersen, Jessica Z K Caldwell, Tobey Betthauser, Julie Elisabeth Oomens, Maria Carrigan, Brian Healy, Jorge Garcia Condado, Sterling C Johnson, Wai-Ying Wendy Yau, Oliver Langford, Michelle Farrell, Rebecca E Amariglio, Dorene M Rentz, Kathryn V Papp, Ron Brookmeyer, Timothy J Hohman, Michael Donohue, Paul S Aisen, Keith A Johnson, Reisa A Sperling, Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health D, Alzheimer’s Disease Neuroimaging Initiative, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) and Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) studies, Harvard Aging Brain Study (HABS), Health & Aging Brain Study – Health Disparities (HABS-HD), and Wisconsin Registry for Alzheimer’s Prevention (WRAP)